News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm is encouraging shareholders of TransMedics Group to visit its website or contact them for more information regarding …
Wasatch Advisors LP reduced its stake in TransMedics Group (NASDAQ:TMDX) by 10.9% in the second quarter but still holds 308,434 shares valued at $20.49 million. The company's recent earnings showed a revenue beat but an EPS miss, leading to mixed analyst ratings with an …
This article lists various Exchange Traded Funds (ETFs) that hold stocks of TransMedics Group, Inc. The ETFs are primarily small-cap and health technology focused, providing investors with diversified exposure to the company. The list includes details such as market value, weight of TransMedics stock, …
Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup positive 56.0%TransMedics Group, Inc. (TMDX) presented a strong, vertically integrated organ transplant platform demonstrating significant financial growth. The company outlined four major expansion initiatives and a clear strategy to achieve $2–$3 billion in revenue, driven by strategic investments in technology, logistics, and new markets. These …
TransMedics Group, Inc. (TMDX) released its Q2 2026 earnings call presentation, reporting an EPS of $0.44, which missed estimates by $0.04, and revenue of $189.95M, beating estimates by $5.96M with a 20.70% year-over-year increase. The article highlights that the presentation was published in conjunction …
A class action securities lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX) on behalf of investors who suffered losses between February 28, 2023, and January 10, 2025. The lawsuit alleges that TransMedics made false statements and concealed practices such as kickbacks, fraudulent overbilling, …
NEW YORK, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). If you currently own shares of TransMedics …
Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup positive 56.0%TransMedics Group Inc (TMDX) shares rose 4.9% to $80.21, but are still estimated to be 48.7% undervalued based on its GF Value™ of $156.29. The stock holds a GF Score™ of 70/100, indicating above-average performance, particularly in growth. However, significant insider selling of $0.7 …
TransMedics Group Inc (TMDX) reported strong Q2 2026 revenue of ~$190 million, up 21% year-over-year, driven by significant growth in service revenue and logistics market share gains. The company raised its full-year revenue guidance while acknowledging a decline in adjusted operating margin due to …
Analysts have cut the 12-month average price target for TransMedics Group, Inc. (TMDX) stock from $106 to $97.3, which still suggests a 20% upside based on its closing price on August 4th. The consensus rating from 12 analysts remains a "Buy," with 8 recommending …
TransMedics (TMDX) reported a Q2 2026 earnings per share miss of 44 cents, a 52.2% year-over-year decrease, despite revenues rising 20.7% to $189.9 million, surpassing estimates. The company's gross margin contracted, and operating expenses significantly increased due to investments in clinical programs and product …
UBS has revised its price target for TransMedics Group (TMDX) down to $77 from $80, while maintaining a "Neutral" rating on the stock. This adjustment comes after the company reported its Q2 2026 earnings, where adjusted net income fell despite a rise in revenue. …
TransMedics Group (TMDX) reported Q2 2026 revenue of $189.9 million, exceeding estimates, which led to a 9.62% rise in share price after market close. Despite revenue growth, profitability decreased, with operating profit down 35.1% and net income down 57.9%. The article also details recent …
Shares of leading, next-gen organ transplant systems specialist TransMedics (NASDAQ: TMDX) are down 8% as of 1 p.m. ET Wednesday after the company reported underwhelming second-quarter earnings. Sales growth of 21% beat analysts' hopes, but adjusted net income was more than halved, falling short …
Canaccord Genuity has reduced its target price for TransMedics Group, Inc. (TMDX.O) from $124 to $95. This information was reported by Reuters on August 5, 2026. The article advises readers that its content reflects only the author's opinion and should not be used as …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. TransMedics Group stock has delivered a 170.9% gain over the past five years, yet …
TransMedics Group reported record Q2 revenue of $190 million, up 21% year over year, driven by strong liver and logistics growth. Despite this, the company lowered its full-year adjusted operating margin outlook to 12.5%-14% due to significant investments in heart and lung adoption, OCS …
TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings, reporting $0.44 EPS, which missed analyst expectations by $0.06, despite revenue of $189.95 million exceeding estimates. The company's shares fell 1.0% to $80.75 following the announcement. Analysts have a mixed view, with an average "Hold" rating and …
For the quarter ended June 2026, TransMedics (TMDX) reported revenue of $189.95 million, up 20.7% over the same period last year. EPS came in at $0.44, compared to $0.92 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $184.17 …
TransMedics (TMDX) came out with quarterly earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.92 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Price below Trend Line 52 weeks -32.1% · Next-week setup positive 56.0%TransMedics Group, Inc. reported its Q2 2026 financial results, showing revenue of $189.9 million, a 20.7% increase year-over-year, primarily driven by OCS Liver sales and NOP service usage. Despite revenue growth, net income declined by 57.9% to $14.7 million, resulting in a diluted EPS …
TransMedics Group, Inc. announced strong financial results for the second quarter of 2026, with total revenue reaching $189.9 million, a 21% increase year-over-year. The company reported a net income of $14.7 million ($0.41 per diluted share) and raised the low end of its full-year …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. TransMedics Group (TMDX) heads into a busy early August, with Q2 2026 results and an earnings call scheduled for August 4 after the …
TransMedics Group (TMDX) announced Q2 2026 financial results, new equity grants to employees, and received fresh UBS research coverage with an $80 price target and Neutral rating. These developments suggest a shifting focus towards internal talent incentives and external analyst attention as the company …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased TransMedics Group, Inc. (TMDX) securities prior to February 3, 2022, and continue to hold them. The investigation seeks to determine if TransMedics and its officers engaged in corporate wrongdoing. …
First Trust Advisors LP significantly increased its stake in TransMedics Group, Inc. by 111.5% in the first quarter, now owning 53,889 shares valued at $5,357,000. Several other institutional investors also expanded their positions, bringing total institutional and hedge fund ownership to 99.67%. Despite this …
TransMedics Group, Inc. announced the grant of non-qualified stock options and restricted stock units to nine new employees as a material inducement for their employment. These grants, totaling 18,762 shares in stock options and 12,414 restricted stock units, were approved by the Compensation Committee …
TransMedics (Nasdaq: TMDX) announced it granted stock options for 18,762 shares and 12,414 restricted stock units to nine new employees on July 29, 2026. These awards serve as material inducements for employment under its Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The stock options …
Needham has maintained a 'Buy' rating on TransMedics Group (TMDX) but lowered its price target from $142.00 to $106.00, reflecting a 25.35% decrease and a more cautious outlook. Despite this, GuruFocus indicates TMDX is 55.4% undervalued, with strong growth potential but challenges in profitability …
TransMedics Group's stock surged 7.5% after UBS initiated coverage with a Neutral rating and an $80 price target. Despite the cautious rating, the market viewed the initiation as validation, pushing the stock to $82.22, above the analyst's target. Investors will monitor future analyst coverage …
Search by ticker symbol or company name and select a result to open its chart.